Skip to content
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
Contact
Contact
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL
June 12, 2023
10:11 pm
Prev
Previous
Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies
Next
Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas
Next
Scroll Up
